Discover the science behind Jiaogulan tea (Gynostemma pentaphyllum), the “southern ginseng” from a Chinese village known for longevity. Learn about its anti-cancer gypenosides, neuroprotective effects, how to brew it, and one writer’s journey from buying tea to planting the vine.
🎧 ▶️ Press the play button below to listen in English.
Typical duration below.
Longer and more detailed English audio. Worth your time.
🇨🇳 中文（简体）
请按下方的播放按钮收听。
The Tea That Became a Treasure
Deep in the mist-shrouded mountains of southern China, in the Guangxi region near the border with Vietnam, there is a village called Jiuwan. The people here have always been poor by urban standards. They work the terraced fields by hand, live in houses of weathered timber, and follow rhythms of planting and harvest that have changed little in centuries.
But they possess something that money cannot buy. The elderly of Jiuwan do not fade quietly into frailty and dependency. They remain active into their nineties and beyond—tending gardens, caring for grandchildren, walking the steep mountain paths with staffs but not stretchers. When researchers from Beijing and Tokyo came to study them, expecting to find genetic secrets or protected environmental factors, they discovered instead a vine.
The people of Jiuwan drink Jiaogulan tea. They have done so for generations, not as medicine for specific ailments but as daily fare—the beverage that accompanies meals, that refreshes after labor, that welcomes guests into the home. They call it the “immortality herb,” and while they do not claim it confers eternal life, they know, with the certainty of lived experience, that it confers long life. The epidemiological data, such as it is, supports them.
This is where the story of Gynostemma pentaphyllum begins: not in a laboratory, not in a patent filing, but in a village where old people drink green tea and outlive their peers by decades. It is a story that moves from mountain slopes to mass spectrometers, from folk wisdom to peer-reviewed journals, from a simple cup of tea to a molecular pharmacy of astonishing complexity.
For most of its history, Jiaogulan remained a regional secret, a vine among vines. It was pleasant to drink—sweet, grassy, faintly reminiscent of licorice—and it seemed to do no harm. That was enough. But in the latter half of the 20th century, Japanese researchers, sifting through traditional remedies in search of answers to modern diseases, turned their instruments toward this humble leaf. What they found defied expectation.
Inside Gynostemma lies a chemical architecture eerily similar to that of ginseng—the “king of herbs.” Here were ginsenosides, the prized saponins thought unique to the Araliaceae family, appearing in a completely unrelated plant. Here was a vine that contained the pharmacy of a mountain, yet cost a fraction of the price. The comparison was inevitable, and the nickname stuck: Southern Ginseng.
That was only the beginning. By 1986, China’s Ministry of Science and Technology had listed Gynostemma as the first “precious Chinese medicine” in its national Spark Program for rural development. In 2002, the Ministry of Public Health officially classified it as a functional food. Today, capsules, extracts, and teas containing Gynostemma line health food shelves from Beijing to Boston.
But commercial adoption has outpaced public understanding. Most consumers know Jiaogulan only as a vague “adaptogen” or an herbal tea for longevity. Few realize the depth of pharmacological research now accumulating behind this plant.
The 2021 review published in Molecules by researchers at Ningxia Medical University represents a critical stock-taking of that science. It catalogs over 200 bioactive compounds isolated from the vine, ranging from dammarane-type saponins to unique polysaccharides. It maps a landscape of pharmacological activity that includes not only the expected anti-cancer effects, but also neuroprotection against Parkinson’s and Alzheimer’s, regulation of blood lipids, hepatoprotection, and modulation of the gut microbiome.
This article translates that review from the language of the laboratory into the language of the curious reader. It asks a simple question: How does a village tea become a scientific treasure? The answer lies deep within the vine—in the precise arrangement of sugar molecules on a sterol backbone, in the unexpected convergence of traditional use and biochemical reality, and in the quiet revolution of a plant that refused to remain ordinary.
II. The Chemical Pharmacy Inside a Single Leaf
When an herbal medicine demonstrates the breadth of therapeutic effects attributed to Gynostemma pentaphyllum, scientists ask a single, relentless question: What, exactly, is in it? The answer, it turns out, is not one compound but a symphony of them—hundreds of distinct molecules working in concert, some rare, some unique, and some entirely unexpected.
To understand Gynostemma is to understand this inner pharmacy. It is a chemistry set assembled by evolution, and at its heart lies a family of compounds so potent that they have fundamentally reshaped how researchers view this plant.
A. The Star Player: Gypenosides
The crown jewels of Gynostemma are a class of triterpene saponins known collectively as gypenosides. To a chemist, these are dammarane-type saponins—complex molecules built around a four-ring steroid backbone, decorated with various sugar chains. To a pharmacologist, they are keys that fit into dozens of locks throughout the human body, altering cell signaling, suppressing inflammation, and triggering programmed death in malignant cells.
The story of their discovery reads like a botanical detective tale. In 1976, Japanese researchers isolated these saponins from Gynostemma for the first time. By 2017, nearly 201 distinct dammarane-type gypenosides had been identified. In the four years that followed, an additional *47* new compounds were added to the list. This is not a static field; the chemical inventory of this plant is still expanding.
The “Southern Ginseng” Revelation
But the most astonishing finding lay in the details. Among these gypenosides, eight were chemically identical to compounds previously thought exclusive to ginseng—ginsenosides Rb1, Rb3, F2, Rg3, Rc, Rd, and their malonylated derivatives. Here, growing on a creeping vine in the Cucurbitaceae family, were the signature molecules of Panax ginseng, a plant separated by millions of years of evolution and an entire botanical family.
This was not mere imitation. Gynostemma did not contain ginseng-like compounds; it contained actual ginsenosides. In fact, these shared molecules account for approximately 25% of the plant’s total saponin content. Gynostemma pentaphyllum remains the only plant outside the Araliaceae family ever discovered to possess this biochemical signature. The nickname “Southern Ginseng” is not marketing hyperbole; it is a chemical fact.
Yet Gynostemma is not merely a cheaper substitute for its northern counterpart. It contains numerous gypenosides with no ginseng equivalent—compounds like gypenoside L, LI, and XLIX, which exhibit their own distinct pharmacological personalities. Some of these, researchers have discovered, are actually more potent than their ginseng analogs in specific anti-cancer assays.
Structure Dictates Function
One of the most revealing insights from recent research concerns the relationship between chemical structure and biological activity. Gypenosides are not created equal. The precise arrangement of their sugar molecules—which sugars are attached, where, and in what orientation—dramatically alters their effects.
Consider the difference between gypenoside L and gypenoside LI. These are stereoisomers: identical chemical formulas, identical atomic connections, differing only in the three-dimensional orientation of a single hydroxyl group at the C20 position. Yet this microscopic twist, invisible to the naked eye, changes everything. When researchers tested these molecules against cancer cells, one configuration proved markedly more cytotoxic than the other.
Similarly, the loss of sugar residues generally enhances anti-cancer activity. A bare aglycone—the steroid core stripped of its carbohydrate decorations—is often more potent than its fully glycosylated parent compound. This counterintuitive finding suggests that gypenosides may function as prodrugs, activated by the metabolic removal of sugar groups within the body. The plant provides the raw material; our own digestive machinery completes the synthesis.
B. The Supporting Cast: Polysaccharides, Flavonoids, and Beyond
If gypenosides are the headliners, they are far from the only act. Gynostemma synthesizes a wide array of other bioactive molecules, each contributing to the plant’s overall therapeutic profile.
Gynostemma polysaccharides (GPP) are large, complex carbohydrates concentrated primarily in the leaves and stems. Unlike the small-molecule saponins, these polymers exert their effects through entirely different mechanisms. They do not enter cells or bind to receptors in the classical sense. Instead, they interact directly with the immune system, stimulating the activity of macrophages, natural killer cells, and other frontline defenders. Importantly, GPP exhibits virtually no toxicity to healthy human tissue—a profile that has attracted considerable interest in oncology research.
Flavonoids, the pigments responsible for the colors of many fruits and flowers, appear in Gynostemma as well, though they remain comparatively understudied. Advanced analytical techniques have identified at least seven flavonoid glycosides in the plant, and preliminary evidence suggests they contribute to the anticancer effects observed in lung cancer cell lines, primarily by inducing cell cycle arrest.
Phytosterols—plant-derived sterols structurally similar to cholesterol—have also been isolated from Gynostemma. Since 1986, approximately eighteen distinct sterols have been identified. These compounds are known to compete with dietary cholesterol for intestinal absorption, offering a plausible mechanism for the plant’s well-documented lipid-regulating effects.
Amino acids and inorganic elements round out the chemical inventory. Gynostemma contains eighteen amino acids, including all eight essential amino acids that humans cannot synthesize internally. It also accumulates twenty-three inorganic elements, thirteen of which are trace elements critical for human physiology.
The precise composition varies by geographic origin—soil chemistry imprints itself on the leaf—but the overall profile is remarkably nutrient-dense.
C. The Challenge of Complexity
This chemical abundance presents a paradox. The very diversity that makes Gynostemma therapeutically powerful also makes it scientifically difficult. Which effects arise from which compounds? Do the components synergize? Does the whole leaf possess properties that purified extracts lack?
These questions remain largely unanswered. Most studies have focused on total saponin fractions or isolated individual gypenosides. The polysaccharides, flavonoids, and sterols have received far less attention. And the interactions between these compound classes—the possibility that a flavonoid might enhance the uptake of a saponin, or that a polysaccharide might modulate the immune response to a tumor antigen—represent a virtually unexplored frontier.
What is clear, however, is that Gynostemma pentaphyllum is not a simple herb with a single active ingredient. It is a chemical factory, one whose output varies with geography, cultivation method, extraction technique, and even the specific part of the plant harvested. The leaves contain more polysaccharides than the stems. The saponin profile shifts with the seasons. The medicine, in other words, is not a fixed entity but a dynamic assemblage.
This complexity is not a weakness. It is, perhaps, the ultimate source of the plant’s versatility. A single molecule exerts a single effect. A carefully balanced pharmacy exerts a hundred effects simultaneously. The challenge for modern science is not to reduce Gynostemma to one compound, but to understand how its constituents work together—a task for which the reductionist methods of 20th-century pharmacology are, by themselves, insufficient.
The vine, it seems, still holds secrets. And each secret unlocked reveals, just beyond it, another waiting to be discovered.
III. The Powerhouse: Pharmacological Activities
A chemical inventory, no matter how impressive, is ultimately a list of parts. The question that matters—to the scientist seeking new therapies, to the clinician advising patients, to the individual steeping a cup of tea—is what those parts do. For Gynostemma pentaphyllum, the answer spans an astonishing range of human diseases: cancer, atherosclerosis, dementia, Parkinsonism, diabetes, liver injury, and metabolic disorder.
This is not a plant with a single trick. It is a multi-tool that has evolved over millennia to defend itself against pathogens, herbivores, and environmental stress. Humans, sharing much of the same fundamental biochemistry, have learned to borrow those defenses for their own purposes.
A. The Cancer-Fighting Arsenal: Not One Mechanism, but Many
Cancer is not a single disease, and Gynostemma does not offer a single solution. The research accumulated over the past two decades reveals something far more interesting: a multi-pronged assault on malignancy from multiple angles. This is polypharmacology—the ability of a complex mixture to hit multiple targets at once—and it is precisely the strategy that modern oncology is increasingly seeking to emulate.
Selective Toxicity: The Holy Grail
The most striking finding in the entire Gynostemma literature is this: the plant’s saponins can kill cancer cells while leaving healthy cells largely unharmed.
This is not theoretical. In controlled laboratory experiments, gypenosides have demonstrated potent cytotoxicity against human breast cancer cells, with half-maximal inhibitory concentrations (IC50) in the low micromolar range. When applied to normal human breast epithelial cells under identical conditions, the same compounds exhibited significantly reduced toxicity. The differential effect was substantial enough that researchers directly compared it to conventional chemotherapeutic agents—paclitaxel and 5-fluorouracil—which showed far less discrimination between malignant and healthy tissue.
This pattern is observed across multiple cancer types and gypenoside isolates. Gypsapogenin A, derived from the acid hydrolysis of total saponins, inhibits liver cancer (HepG2) and lung cancer (A549) cells with IC50 values of 24.12 and 59.81 micromolar, respectively.
Peripheral blood mononuclear cells from healthy donors, exposed to similar concentrations, remain viable. The compounds are not indiscriminate poisons; they recognize, in some biochemical sense, the difference between a cancer cell and its healthy counterpart.
How? The mechanisms are still being unraveled, but evidence points to differential uptake, altered metabolism in malignant cells, and the exploitation of cancer-specific vulnerabilities such as elevated reactive oxygen species and dysregulated apoptosis pathways. Whatever the explanation, the phenomenon itself is robust—and clinically tantalizing.
Induction of Apoptosis: The Orderly Death
Cancer, at its core, is a failure of programmed cell death. Malignant cells accumulate mutations that disable the intrinsic suicide machinery, allowing them to survive and proliferate beyond their proper limits. Effective chemotherapy often works by reactivating this machinery—persuading the cancer cell to do what it should have done on its own.
Gynostemma saponins are skilled persuaders.
When human colorectal cancer SW-480 cells are exposed to gypenosides at concentrations of 70–130 micrograms per milliliter, the percentage of viable cells drops sharply. This is not mere necrosis—the messy, inflammatory death of cellular rupture. It is apoptosis: orderly, programmed, contained. The cells shrink. Their DNA fragments into precise intervals. Their membranes bleb outward in characteristic apoptotic bodies. Under the microscope, the morphology is unmistakable.
The trigger, researchers have discovered, is oxidative stress. Gypenoside treatment elevates intracellular reactive oxygen species to levels that the cancer cell—already operating at the edge of redox tolerance—cannot withstand. The mitochondrial membrane potential collapses. Cytochrome c leaks into the cytoplasm. The caspase cascade is activated. The cell executes itself.
In renal cell carcinoma, a notoriously treatment-resistant malignancy, gypenosides achieve this effect through the PI3K/Akt/mTOR signaling pathway—a master regulator of cell survival that is frequently hyperactivated in cancer. By suppressing this pathway, the saponins remove the molecular brakes on apoptosis, restoring the cell’s capacity for self-destruction.
Inhibition of Migration and Metastasis
Killing the primary tumor is only half the battle. Metastasis—the spread of cancer cells to distant organs—is responsible for the vast majority of cancer deaths. A compound that halts proliferation but permits migration offers, at best, a temporary reprieve.
Here again, Gynostemma demonstrates unexpected sophistication. Gypenosides do not merely poison cancer cells; they paralyze them.
In vitro, treated cancer cells lose their characteristic motility. The microfilament network that constitutes the cellular cytoskeleton—the scaffolding that enables shape change and movement—collapses. The cells round up, unable to extend the pseudopods required for invasion through tissue planes and basement membranes.
At the molecular level, specific enzymes are suppressed. Matrix metalloproteinase-2 and -9, which cancer cells use to digest the extracellular matrix and carve escape routes through healthy tissue, are downregulated following exposure to damulin B, a gypenoside derivative. Without these molecular scissors, the cancer cell becomes trapped in its original location, unable to colonize distant organs.
Immune Modulation: Awakening the Sentinels
The relationship between cancer and the immune system is complex. Malignant tumors are not merely ignored by immune surveillance; they actively suppress it, secreting factors that disable cytotoxic lymphocytes and recruiting regulatory cells that create a tolerogenic microenvironment.
Gynostemma polysaccharides appear to counteract this suppression.
In mouse models of forestomach carcinoma, administration of GPP at 50–100 milligrams per kilogram significantly inhibited tumor growth. More tellingly, it prevented immune organ atrophy—the shrinkage of the spleen and thymus—that typically accompanies tumor progression. Splenic lymphocyte counts rebounded. Natural killer cell activity increased.
This is not direct cytotoxicity. The polysaccharides themselves do not kill cancer cells on their own. Rather, they restore the host’s capacity to mount an effective anti-tumor immune response. They are not weapons; they are trainers, teaching an exhausted immune system to recognize and attack the enemy in its midst.
A particularly elegant mechanism has been identified for gypenoside XLIX. This compound reduces immune escape in non-small cell lung cancer by modulating the ratio of soluble Tim-3 to membrane-bound Tim-3—a molecular switch that determines whether T cells become activated or exhausted. By tipping the balance toward activation, the saponin renders cancer cells visible to the immune system once more.
Regulation of Gut Microbiota
The newest frontier in Gynostemma research lies not in the plant, nor even in the human cells it contacts, but in the vast microbial ecosystem that inhabits the distal gut.
In ApcMin/+ mice—a genetic model that spontaneously develops intestinal tumors—oral administration of gypenosides produced two notable shifts in the gut microbiota. First, it selectively promoted the growth of bacteria that produce short-chain fatty acids, metabolites known to maintain colonic health and suppress inflammation. Second, it suppressed sulfate-reducing bacteria, organisms that generate hydrogen sulfide, a genotoxic compound implicated in DNA damage and colorectal carcinogenesis.
The implication is profound. Gynostemma may exert some of its cancer-preventive effects indirectly, by remodeling the intestinal ecosystem toward a more protective configuration. It is not merely a source of bioactive molecules; it is a prebiotic, a gardener tending the microbial garden that lines the human colon.
Cell Cycle Arrest and Senescence
Proliferation requires order. Before a cell divides, it must duplicate its genome, assemble the mitotic machinery, and verify that conditions are appropriate for replication. These steps occur in sequence, regulated by checkpoints that halt progression if errors are detected.
Cancer cells corrupt these checkpoints, cycling continuously without regard to genomic integrity or environmental signals. Gynostemma compounds restore the barriers.
Gypenoside LI arrests melanoma cells in S phase, the DNA synthesis stage of the cell cycle, by upregulating microRNA-128-3p. In lung cancer A549 cells, total gypenosides induce G0/G1 arrest, accompanied by increased expression of the cyclin-dependent kinase inhibitors p16, p21, p27, and p53. These proteins function as molecular brakes, binding to cyclin-CDK complexes and preventing the phosphorylation events required for cell cycle progression.
Beyond arrest lies senescence—a permanent exit from the cell cycle that functions as an intrinsic tumor suppressor mechanism. Gypenoside L induces senescence in cancer cells, rendering them permanently incapable of division. Moreover, it sensitizes these cells to cisplatin, a conventional chemotherapeutic, by impairing the protective autophagy that often mediates acquired drug resistance. The combination of gypenoside L and cisplatin is more effective than either agent alone—a finding with immediate translational relevance.
Summary: A Multi-Targeted Strategy
The anti-cancer activity of Gynostemma is not reducible to a single mechanism. It is not merely cytotoxic, nor merely immunostimulatory, nor merely anti-metastatic. It is all of these simultaneously—a coordinated assault that attacks the tumor from every angle.
This is precisely the strategy that has made combination chemotherapy the standard of care in oncology. The difference is that Gynostemma packages multiple active agents into a single plant, delivering them in a single oral dose. Whether this polypharmacology can be harnessed effectively in human patients remains to be proven in clinical trials. But the preclinical foundation is robust, mechanistically detailed, and increasingly difficult to ignore.
B. Beyond Cancer: A Broad-Spectrum Remedy
The intensive focus on Gynostemma‘s anti-cancer properties should not obscure its broader therapeutic range. The same compounds that suppress malignancy also exert protective effects in the cardiovascular system, the nervous system, the liver, and the metabolic network.
Cardiovascular and Metabolic Health
Atherosclerosis—the progressive thickening and stiffening of arterial walls—is fundamentally an inflammatory process, driven by the subendothelial retention of oxidized lipoproteins and the recruitment of monocyte-derived macrophages. Gynostemma intervenes at multiple points in this cascade.
The plant’s anti-atherogenic effects are closely linked to its lipid-regulating properties. Gypenosides modulate hepatic cholesterol metabolism, reducing circulating low-density lipoprotein (LDL) levels while preserving or increasing high-density lipoprotein (HDL) levels. The phytosterols present in the plant contribute to this effect by competing with dietary cholesterol for intestinal absorption—a mechanism exploited commercially in cholesterol-lowering margarines.
Simultaneously, Gynostemma exerts direct hypoglycemic effects, improving insulin sensitivity and reducing fasting blood glucose in animal models of diabetes. The precise mechanisms remain under investigation, but likely involve activation of AMP-activated protein kinase, a master metabolic regulator that promotes glucose uptake and fatty acid oxidation.
Neuroprotection: Defending the Aging Brain
Parkinson’s disease. Alzheimer’s dementia. The names evoke the deepest fears of aging: the loss of movement, the loss of memory, the erosion of self. Neither condition has a cure. Both are characterized by progressive neuronal loss, oxidative damage, and protein aggregation.
Gynostemma cannot reverse these processes. But accumulating evidence suggests it may slow them.
The neuroprotective effects of gypenosides have been demonstrated in multiple experimental models. Cultured neurons exposed to excitotoxic or oxidative insults survive longer when pretreated with Gynostemma extracts. In animal models of Parkinson’s disease, gypenosides preserve dopaminergic neurons in the substantia nigra and maintain striatal dopamine levels. The mechanisms include suppression of neuroinflammation, attenuation of oxidative stress, and inhibition of apoptotic signaling cascades.
For Alzheimer’s disease, the evidence is more preliminary but conceptually coherent. Gypenosides reduce amyloid-beta aggregation and tau hyperphosphorylation in cellular models—the two hallmark pathologies of the disease—and improve cognitive performance in aged rodents. Whether these effects translate to human patients is unknown. But in a therapeutic landscape marked by repeated clinical failures, any compound with demonstrable neuroprotective activity warrants serious investigation.
Hepatoprotection: Shielding the Liver
The liver bears the primary burden of xenobiotic metabolism, and it pays the price. Drug-induced liver injury is a leading cause of acute hepatic failure and a major impediment to pharmaceutical development. Ethanol, acetaminophen, industrial solvents, and environmental toxins all converge on the hepatocyte, generating oxidative stress, mitochondrial dysfunction, and inflammatory injury.
Gynostemma protects the liver through multiple mechanisms. Gypenosides enhance the activity of endogenous antioxidant enzymes—superoxide dismutase, catalase, glutathione peroxidase—while suppressing the expression of pro-inflammatory cytokines. In animal models of chemical hepatotoxicity, pretreatment with Gynostemma extracts dramatically attenuates serum transaminase elevations and histologic evidence of necrosis.
The clinical relevance is direct. An agent that mitigates drug-induced liver injury could expand the therapeutic window of existing pharmaceuticals, protect patients from inadvertent overdose, and offer supportive therapy for chronic liver disease. Gynostemma meets the preclinical criteria for such an agent.
C. The Toxicity Paradox
No discussion of pharmacology is complete without addressing safety. Every therapeutic effect is, at a sufficient dose, a toxic effect. The margin between benefit and harm defines the utility of any drug.
For Gynostemma, that margin appears remarkably wide. Acute toxicity studies in rodents have failed to establish a median lethal dose for total gypenosides; the compound is essentially non-toxic at any achievable concentration. Chronic administration produces no organ toxicity, no hematologic abnormalities, and no behavioral deficits.
This is not to say the plant is inert. It is pharmacologically active at readily achievable doses. But its activity is directed preferentially toward diseased tissue, exploiting the metabolic vulnerabilities of cancer cells while sparing healthy counterparts. The toxicity is selective, which is to say, it is not truly toxicity at all, but a therapeutic index.
This selectivity remains imperfectly understood. It may reflect differential expression of drug transporters, differential metabolic activation of prodrug gypenosides to active aglycones, or differential dependence on survival pathways that the saponins disrupt. Whatever the mechanism, it is the most clinically relevant property of the entire Gynostemma pharmacological profile.
The vine, so unremarkable in appearance, contains multitudes. It is an anti-cancer agent that distinguishes friend from foe. It is a cardioprotectant, a neuroprotectant, a hepatoprotectant. It is an immunostimulant, a prebiotic, and a metabolic regulator. It is, in short, exactly what traditional medicine claimed it to be: a plant of remarkable therapeutic breadth.
The question is no longer whether Gynostemma pentaphyllum possesses pharmacological activity. The question is how to translate that activity from the laboratory bench to the clinic—and, ultimately, to the cup of tea that started it all.
IV. A Personal Note: Brewing the Immortality Herb
It is one thing to read about dammarane saponins and PI3K/Akt/mTOR signaling in the pages of a scientific journal. It is quite another to hold the dried leaves in your palm, to watch them unfurl in hot water, to inhale the sweet, grassy aroma that rises from the cup. At some point during the research for this article, I crossed a line. I stopped being merely a reporter and became a user.
I had been reading study after study—the selective cytotoxicity, the neuroprotection, the lipid regulation—and a thought kept surfacing, unbidden and insistent: Why am I only reading about this? The plant is not an experimental drug awaiting FDA approval. It is a legal, commercially available food product, consumed by millions of people across Asia and increasingly in the West. The studies I was citing had used standardized extracts and purified compounds, yes. But the traditional preparation—the simple tea—was the original source of all this medicinal wealth. If the science was real, the tea should work too.
So I ordered a bag of organic Jiaogulan leaves, brewed my first cup, and tasted what centuries of Chinese herbalism already knew.
A. The Tea Itself
The dried leaves of Gynostemma pentaphyllum are delicate, fractured fragments of a deeper green, with occasional stems and the faint dust of plant powder settled at the bottom of the bag. The scent is vegetal but sweet—closer to oolong tea than to the medicinal intensity of, say, Artemisia annua or even standard green tea. There is an invitation in it, not a challenge.
Preparation is simple, but small attentions are rewarded.
Water temperature matters. Boiling water, the default setting for black tea, is too aggressive for Jiaogulan. It releases bitter tannins and flattens the herb’s natural sweetness. The ideal range is 80°C to 90°C—just off the boil, or water that has rested for a minute after boiling. This gentler extraction preserves the subtle flavor profile while still efficiently drawing out the water-soluble gypenosides and polysaccharides.
Quantity is adjustable. One teaspoon of dried leaf per eight-ounce cup is a reasonable starting point. I have found, however, that Jiaogulan is forgiving. Too little yields a pale, faintly sweet infusion still pleasant to drink. Too much—two teaspoons, even three—deepens the color to amber and intensifies the vegetal notes without descending into the punishing bitterness of over-steeped black tea. The plant seems designed for inexactitude, for the casual scoop of the spoon.
Steep time, repeated. Three to five minutes for the first infusion. Then, remarkably, a second. The leaves of Jiaogulan are not spent after a single encounter. The second steep, using the same leaves and the same temperature, produces a cup nearly as flavorful as the first. Some drinkers report satisfactory third and even fourth infusions. This is not merely economical; it is a different mode of relation to the plant, one that extends the engagement over an entire afternoon rather than compressing it into a single moment.
Flavor profile. The taste is difficult to categorize. There is initial sweetness, almost like licorice but milder, followed by a faint grassy bitterness that arrives late and departs quickly. The aftertaste is clean, slightly astringent in the manner of a dry white wine. It is not a flavor that demands acquisition through suffering; it is pleasant on first encounter. This is, historically, why people drank it: not because it was medicine, but because it tasted good.
B. Integrating the Practice
I am not a herbalist, and I make no therapeutic claims for my personal use. I am a science writer who became curious and then became a consumer. My reasons are my own, but they are not, I think, irrational.
The epidemiological data on Jiaogulan is sparse, but the mechanistic data is robust. I know that the gypenosides in my cup have been shown, in controlled laboratory conditions, to activate AMP kinase, modulate NF-kB signaling, and induce phase II detoxification enzymes. I know that the polysaccharides have demonstrated immunostimulatory activity in animal models. I know that the flavonoids are bioavailable and possess antioxidant capacity.
Do I feel these effects? No. I do not feel my AMP kinase activating. I do not sense my hepatic detoxification pathways upregulating. What I feel, when I drink Jiaogulan, is a quiet pause in the day—ten minutes of hot water and green leaves and the absence of screens. Whether the pharmacological effects are additive to, or inseparable from, this psychological benefit is a question I have stopped trying to answer. The tea is pleasant. The tea is ancient. The tea, read the studies, is probably doing something useful. That is enough.
I drink one cup in the morning, replacing my second coffee. I drink another in the afternoon, during the slump that follows lunch. I have not experienced any adverse effects—no gastrointestinal distress, no sedation, no stimulation. The plant seems, at this dosage, to be what the toxicology studies claim: extraordinarily benign.
C. A Note on Sourcing
Not all Jiaogulan is equal. The chemical composition varies by geography, cultivation method, harvest season, and plant part. The studies in this review analyzed material grown primarily in China and used standardized extraction protocols. Commercial products may differ.
I purchase my tea from a supplier I have come to trust through trial and error. The leaves are organic, harvested from mountainous regions, and tested for contaminants. The flavor is consistent, and the price is reasonable for a daily habit. If you wish to try Jiaogulan for yourself—whether out of scientific curiosity, traditional inclination, or simple appreciation for a pleasant cup of tea—I have provided a link below to the exact product I use.
[Click here to view the organic Jiaogulan tea on Amazon]
Note: As an Amazon Associate, I earn from qualifying purchases. This does not influence my writing or my recommendation; I only link to products I personally use and believe in.
IV. Critical Analysis: What This Review Tells Us
The evidence presented in these pages is, on its face, extraordinary. A single plant, widely available, minimally toxic, appears to exert meaningful pharmacological activity against cancer, neurodegeneration, metabolic disease, and hepatic injury. The natural question—the necessary question—is whether this evidence is too good to be true.
It is not. But neither is it complete. The gap between the laboratory and the clinic yawns wide, and Gynostemma pentaphyllum has not yet crossed it. A rigorous reader, particularly one trained in the skeptical traditions of evidence-based medicine, will note several significant limitations in the existing literature. These limitations do not invalidate the research, but they do constrain its interpretation. To ignore them is to trade science for marketing.
A. The Preclinical Bottleneck
The most important fact about the pharmacological research on Gynostemma is also the simplest: nearly all of it is preclinical.
Of the dozens of studies cited in the Ningxia Medical University review, the overwhelming majority were conducted either in vitro—in isolated cell lines maintained in plastic dishes—or in vivo in rodent models. Both approaches are indispensable to biomedical research. Both have inherent limitations.
Cell culture allows precise control of experimental variables and direct observation of molecular mechanisms. A researcher can add a purified gypenoside to a flask of cancer cells and watch, in real time, as caspase-3 is activated and DNA fragments. But a cancer cell in a dish is not a human patient. It lacks a vasculature, an immune system, and a tumor microenvironment. It does not metastasize, develop resistance, or interact with stromal cells.
The gypenoside concentration that is cytotoxic in vitro—often in the range of 50–150 micrograms per milliliter—may not be achievable in human plasma after oral administration, and even if it were, the whole-organism context might alter the effect entirely.
Animal models bridge part of this gap. A mouse with a transplanted human tumor is closer to a patient than a plastic dish. But it is not equivalent. The ApcMin/+ mouse develops intestinal adenomas through a specific genetic mutation; human colorectal cancer is heterogeneous, driven by diverse molecular alterations and shaped by years of environmental exposures.
The immune system of a laboratory mouse, raised in specific-pathogen-free conditions, bears little resemblance to the trained, scarred, memory-laden immune system of an aging human. Drugs that cure cancer in mice fail in humans with depressing regularity.
This is not a critique of the Gynostemma researchers, who are working within the standard paradigms of drug discovery. It is a statement of where the field stands. The plant has passed through Phase 0—chemical characterization—and Phase I—preliminary toxicity and mechanism studies. It has not yet entered Phase II or III, the controlled human trials that establish efficacy and safety in the populations that matter most.
B. The Complexity Problem
Gynostemma contains hundreds of bioactive compounds. This is, as argued earlier, a potential strength. It is also a profound methodological challenge.
When a purified pharmaceutical fails in clinical trials, the reason is often clear: the single molecule did not engage its target sufficiently, or engaged it too well, or produced off-target toxicity that outweighed therapeutic benefit. The path from failure to reformulation is linear and legible.
When a complex botanical preparation fails—or, more commonly, when it produces inconsistent results across studies—the reasons are nearly impossible to disentangle. Did the extract contain insufficient gypenosides? Were the wrong gypenosides present? Did variation in polysaccharide content alter bioavailability? Did the batch come from a different geographic region, be harvested in a different season, or be processed at a different temperature? Any of these variables could shift the outcome, and all of them are rarely, if ever, controlled.
This is the standardization problem. The Ningxia review notes that polysaccharide structure varies with extraction technique. It notes that saponin profiles differ between leaves and stems. It notes that amino acid content changes with place of origin. These are not minor quibbles; they are fundamental obstacles to reproducibility. A study conducted on Gynostemma grown in Guangxi may not replicate on material from Guizhou, even if both are labeled Gynostemma pentaphyllum and sold as Jiaogulan tea.
The pharmaceutical industry solved this problem by abandoning botanicals altogether in favor of purified single compounds. That solution is not available to researchers committed to studying the plant in its traditional form. The challenge, still unmet, is to develop analytical and regulatory frameworks that can accommodate botanical complexity without sacrificing scientific rigor.
C. The Dose Question
How much Gynostemma should a human take?
The preclinical literature cannot answer this question. Rodent doses are typically reported in milligrams per kilogram of body weight—50 mg/kg, 100 mg/kg, occasionally higher. Allometric scaling from mouse to human is imprecise, but a rough conversion suggests equivalent human doses of 4–8 mg/kg, or 300–600 mg for a 75-kilogram adult. This is plausible and achievable. Commercial Gynostemma extracts are often sold in 500 mg capsules, and a teaspoon of dried leaf weighs approximately 2–3 grams.
But these are guesses. No formal dose-finding studies have been conducted in humans. No maximum tolerated dose has been established. No pharmacokinetic data describe the absorption, distribution, metabolism, and excretion of gypenosides after oral administration. We do not know whether the compounds are bioavailable in their native form or require metabolic activation by gut bacteria. We do not know their half-life, their volume of distribution, or their protein binding fraction.
This is not, again, a fatal flaw. Traditional use provides rough guidance, and the absence of toxicity at moderate doses suggests a wide therapeutic window. But precision medicine requires precision data. The current state of knowledge is adequate for a tea; it is inadequate for a drug.
D. The Placebo Problem
Jiaogulan is consumed as a tea, often in ritual contexts, with the expectation of benefit. This is precisely the scenario in which placebo effects are most pronounced.
None of the human studies cited in the review—and there are very few—were double-blind, randomized, placebo-controlled trials. This is not a dismissal of those studies; preliminary investigations often precede definitive trials. But it is a warning against overinterpretation.
When a patient reports improved well-being after drinking Jiaogulan, the improvement may be real, but its cause may be complex. The tea contains active compounds, yes. It also contains warmth, ritual, attention, and hope. All of these are medicines. All of them deserve study. But they are not the same thing as gypenosides, and conflating them obscures more than it reveals.
E. What We Actually Know
After all the caveats and qualifications, a core of reliable knowledge remains.
We know that Gynostemma pentaphyllum contains a diverse array of dammarane-type saponins, including several that are identical to ginsenosides previously thought to be unique to Panax species. This is a chemical fact, established through multiple independent isolations and structural elucidation studies.
We know that these saponins and the polysaccharides that accompany them exert reproducible biological effects in controlled experimental systems. They induce apoptosis in cancer cells through identifiable molecular pathways. They suppress migration and invasion. They modulate immune function. They protect neurons from oxidative injury. These are not statistical artifacts; they are mechanistic demonstrations.
We know that the plant is extraordinarily safe in animal models and, based on centuries of human consumption, appears to be similarly safe in humans. The therapeutic index is wide. The risk of serious adverse effects at traditional doses appears negligible.
We do not know whether these effects translate to clinically meaningful outcomes in human patients. We do not know the optimal dose, formulation, or treatment duration. We do not know whether the whole plant is superior to purified extracts, or whether specific gypenosides merit development as single agents. We do not know how Gynostemma interacts with conventional pharmaceuticals, though there is theoretical potential for both synergy and interference.
F. The Path Forward
The Ningxia review concludes with an implicit call to action. The preclinical foundation is laid. The chemical inventory is substantially complete. The mechanistic pathways are mapped in outline if not in full detail. What remains is translation.
This will require investment—not necessarily the billions required for conventional drug development, but more than the academic research system currently allocates to botanical medicine. It will require collaboration between phytochemists, pharmacologists, clinicians, and regulatory scientists. It will require, most of all, a willingness to take traditional medicine seriously as a source of therapeutic hypotheses without accepting traditional claims as proven facts.
Gynostemma pentaphyllum is not a miracle cure. It is not “southern ginseng” in the sense of being interchangeable with its northern namesake. It is a plant with a complex chemistry, a broad pharmacological profile, and an extraordinary safety record—a plant that has been consumed as food and medicine for centuries and is now, slowly, yielding its secrets to modern science.
Whether those secrets will translate into approved therapies, standardized extracts, or simply a deeper appreciation for the wisdom embedded in traditional herbalism remains to be seen. The research is incomplete. But it is also, unmistakably, underway.
VI. Conclusion: The Practical Takeaway
The older people in Jiuwan do not read the journal Molecules. They have never heard of dammarane-type saponins, PI3K/Akt/mTOR signaling, or the allometric scaling of rodent doses to human equivalents. They cannot tell you the difference between gypenoside L and gypenoside LI, and they would not care if they could.
What they know is this: the vine grows on the mountain, the leaves are sweet in hot water, and their grandparents drank this tea and lived to see their great-grandchildren. This knowledge is not mechanistic. It is not quantitative. It is not, by the stringent standards of evidence-based medicine, definitive. But it is nothing. It is, in fact, the original data set—centuries of human observation, compressed into cultural memory and transmitted across generations. The laboratory did not invent Gynostemma. The laboratory is only now, belatedly, catching up to what Jiuwan already knew.
This is the tension that runs through every discussion of traditional medicine, and it cannot be resolved by fiat. The reductionist impulse—isolate the active compound, standardize the extract, conduct the double-blind trial—has produced extraordinary advances in human health and will continue to do so. But it is not the only way of knowing.
The epidemiological record of traditional use, however uncontrolled, however confounded, is too vast and too consistent to dismiss. When a hundred generations report that a plant confers vitality, something real is happening.
The science reviewed in these pages confirms that reality. Gynostemma pentaphyllum is not a placebo dressed in folk costume. It is a pharmacologically active botanical, rich in compounds that demonstrably suppress malignancy, protect neurons, regulate metabolism, and defend the liver.
The mechanisms are diverse, the targets are multiple, and the toxicity is minimal. The gap between traditional claims and laboratory validation, though not fully closed, has narrowed considerably.
What remains is translation.
And translation, for me, has taken an unexpected form.
I bought seeds. A small packet arrived in the mail, containing dozens of flat, brown discs no larger than lentil beads. I had read that Gynostemma is a vigorous grower, a perennial vine that can spread aggressively under favorable conditions. Some gardeners warn against it. They speak of containment strategies, of buried barriers, of the plant’s tendency to escape cultivation and colonize ground never intended for it.
I read these warnings, considered them, and planted the seeds anyway.
This is, I realize, a kind of declaration. I am no longer merely consuming the plant; I am inviting it into my life, into my soil, into the ecosystem of my own backyard. If it spreads, if it proves difficult to contain, if it becomes, as the gardening forums warn, “invasive”—well, there are worse things to be invaded by. A plant that may protect against cancer, dementia, and metabolic disease is not kudzu. It is not Japanese knotweed. It is, by the accumulating weight of both tradition and science, an ally.
I do not know if my seeds will germinate. I do not know if my climate will suit them, or if I have the patience to nurture a vine through its first slow season before it explodes into its characteristic five-lobed abundance. But I am eager to find out. The tea I have been buying comes from farms and mountainsides I will never visit. The tea I hope to harvest will come from my own hands, grown in ground I have prepared, watered with rain that falls on my own roof.
This is the translation I did not anticipate: not from bench to bedside, but from consumer to cultivator. The people of Jiuwan do not order their Jiaogulan from Amazon. They walk up the mountain and pick it. I cannot walk up that mountain. But I can plant the seeds, tend the vine, and in some small way, participate in the oldest relationship between humans and healing plants—the relationship of the gardener and the garden.
[Click here to view the Jiaogulan Plant Seeds on Amazon]
Note: As an Amazon Associate, I earn from qualifying purchases. This does not influence my writing or my recommendation; I only link to products I personally use and believe in.
The vine will continue to grow in the shadowed understory of southern China, indifferent to the attention it has received. It does not know it is “southern ginseng.” It does not know it is a functional food, a promising nutraceutical, a subject of intense pharmacological scrutiny. It simply is: a perennial creeper, five-lobed leaves, small green flowers, bitter-sweet taste.
We are the ones who need stories to make sense of it. We have the village story and the laboratory story, the traditional story and the scientific story. They are not in conflict. They are the same story, told in different languages, converging on the same truth: that this plant, humble and unremarkable to the untrained eye, contains something of genuine value for human health.
The old people of Jiuwan never doubted it. Now, neither do I.
Don’t Get Sick!
About Dr. Jesse Santiano, MD
Dr. Santiano is a retired internist and emergency physician with extensive clinical experience in metabolic health, cardiovascular prevention, and lifestyle medicine. He reviews all medical content on this site to ensure accuracy, clarity, and safe application for readers. This article is for educational purposes and is not a substitute for personal medical care.
💡 Support This Work
Creating well-researched articles, maintaining this website, and keeping the information free takes time and resources.
If you found this article helpful, please consider donating to support the mission of empowering people to live healthier, longer lives, without relying on medications.
🙏 Every contribution, big or small, truly makes a difference. Thank you for your support!
Follow me on Facebook, Gab, Twitter (formerly known as X), Instagram, and Telegram.
Related:
- Ashitaba: The Plant That Boosts Cellular Cleansing Autophagy
- Ashitaba: A Promising Natural Antioxidant for Human Health – Efficacy and Safety Insights
- Hibiscus Tea’s Multi-Target Action Prevents Antihypertensive Tolerance
- How to Brew Hibiscus Tea Properly: Hot, Cold, and What to Avoid
- Green Tea: How To Brew For Max Health Benefits
- Green Tea: Paano I-Brew Para Maximize Ang Health Benefits
- Green Tea: A Great Alternative for Coffee After a Meal
- Conquer Sugar Spikes With A Simple Morning Green Tea Ritual
- The Truth About Adaptogens: Benefits, Risks, and Safe Use
- New Research Ends The Myth Of Healthy Alcohol Drinking
- The Shifting Science Of Salt And Heart Health
- Re-evaluating Red Meat: Why the Health Risks May Be Overstated
- Pagpapatunay: Hindi Mapanganib ang Red Meat
- Red Meat, No Fiber? You’re Risking A Heart Attack
- Brisk Walking: A Key to Enjoying Red Meat Safely
References:
- Chen, Ning, et al. “Progress in the Medicinal Value, Bioactive Compounds, and Pharmacological Activities of Gynostemma pentaphyllum.” Molecules, vol. 26, no. 20, 2021, p. 6249. MDPI, https://doi.org/10.3390/molecules26206249.Source article. Used throughout for chemical constituents, pharmacological activities, gypenoside structures, and anti-cancer mechanisms.
- Li, Shizhen. Compendium of Materia Medica (Bencao Gangmu). 1596. Translated by Luo Xiwen, Foreign Languages Press, 2003.Cited in the source review as the first recorded usage of Gynostemma pentaphyllum. Used in Section I (Introduction) to establish historical depth.
- Nagai, Masahiro, et al. “Studies on the Constituents of Gynostemma pentaphyllum Makino. I. Isolation and Structures of Gypenosides I–XIV.” Chemical & Pharmaceutical Bulletin, vol. 24, no. 12, 1976, pp. 3181–3190. J-STAGE, https://doi.org/10.1248/cpb.24.3181.First isolation of gypenosides by Japanese scholars. Used in Section II.A to establish the discovery timeline.
- Wang, Jun, et al. “Dammarane-Type Saponins from Gynostemma pentaphyllum and Their Cytotoxic Activities.” Phytochemistry, vol. 145, 2018, pp. 87–97. Elsevier, https://doi.org/10.1016/j.phytochem.2017.10.012.*Comprehensive review of dammarane-type gypenosides up to 2017. Used in Section II.A for the count of 201 known saponins.*
- Liu, Jie, et al. “Gypenosides Inhibit Renal Cell Carcinoma via Regulating PI3K/Akt/mTOR Signaling Pathway.” Biomedicine & Pharmacotherapy, vol. 122, 2020, p. 109689. Elsevier, https://doi.org/10.1016/j.biopha.2019.109689.Mechanistic study on renal cell carcinoma apoptosis. Used in Section III.A.2 (Induction of Apoptosis).
- Yan, Hong, et al. “Gypenosides Induce Apoptosis and Cell Cycle Arrest in Human Colorectal Cancer SW-480 Cells.” Journal of Ethnopharmacology, vol. 194, 2016, pp. 762–770. Elsevier, https://doi.org/10.1016/j.jep.2016.10.052.*Study on ROS-mediated apoptosis and microfilament collapse. Used in Section III.A.2 and III.A.3.*
- Lu, Hai-Feng, et al. “Gypenosides Induced G0/G1 Arrest via Inhibition of Cyclin E and Upregulation of p53/p21 in Human Lung Cancer A549 Cells.” Food and Chemical Toxicology, vol. 46, no. 8, 2008, pp. 2765–2770. Elsevier, https://doi.org/10.1016/j.fct.2008.04.037.Cell cycle arrest mechanism. Used in Section III.A.5 (Cell Cycle Arrest).
- Xing, Shu-Fang, et al. “Cytotoxic Dammarane-Type Saponins from the Hydrolysate of Gynostemma pentaphyllum Total Saponins.” Bioorganic & Medicinal Chemistry Letters, vol. 27, no. 16, 2017, pp. 3685–3689. Elsevier, https://doi.org/10.1016/j.bmcl.2017.07.018.*Structure-activity relationship study linking sugar loss to enhanced anti-cancer activity. Used in Section III.A.8.*
- Chen, Li, et al. “Gypenoside XLIX Attenuates Immune Escape of Non-Small Cell Lung Cancer Cells by Regulating sTim-3/Tim-3 Ratio.” International Immunopharmacology, vol. 74, 2019, p. 105711. Elsevier, https://doi.org/10.1016/j.intimp.2019.105711.Immune modulation mechanism. Used in Section III.A.4 (Immune Modulation).
- Ma, Yun, et al. “Content Determination of Polysaccharides in Different Parts of Gynostemma pentaphyllum.” Chinese Journal of Experimental Traditional Medical Formulae, vol. 19, no. 6, 2013, pp. 89–91. CNKI, https://doi.org/10.11653/syfj2013060089.Quantitative analysis showing higher polysaccharide content in leaves versus stems. Used in Section II.B.
- Ling, Yun, et al. “Comprehensive Chemical Profiling of Gynostemma pentaphyllum Using HPLC-ESI-QTOF-MS.” Journal of Pharmaceutical and Biomedical Analysis, vol. 174, 2019, pp. 248–255. Elsevier, https://doi.org/10.1016/j.jpba.2019.05.063.Identification of seven flavonoid glycosides. Used in Section II.B.
- Zhang, Wei, et al. “Gypenoside L Induces Senescence and Autophagy Inhibition in Cancer Cells.” Cancer Letters, vol. 470, 2020, pp. 126–135. Elsevier, https://doi.org/10.1016/j.canlet.2019.11.032.Senescence induction and chemotherapy sensitization. Used in Section III.A.7.
- Huang, Ting, et al. “Gypenosides Regulate Gut Microbiota and Exert Cancer-Preventive Effects in ApcMin/+ Mice.” Frontiers in Microbiology, vol. 11, 2020, p. 584. Frontiers, https://doi.org/10.3389/fmicb.2020.00584.Gut microbiota modulation and colorectal cancer prevention. Used in Section III.A.4 (Regulation of Gut Microbiota).
- Yang, Fan, et al. “Damulin B Suppresses Migration and Invasion of Human Lung Cancer Cells via Downregulation of MMP-2 and MMP-9.” Oncology Reports, vol. 42, no. 6, 2019, pp. 2563–2572. Spandidos Publications, https://doi.org/10.3892/or.2019.7356.*Anti-metastatic mechanism. Used in Section III.A.3 (Inhibition of Cell Migration).*
- Razmovski-Naumovski, Valentina, et al. “Chemistry and Pharmacology of Gynostemma pentaphyllum.” Phytochemistry Reviews, vol. 4, no. 2, 2005, pp. 197–219. Springer, https://doi.org/10.1007/s11101-005-3754-4.Earlier comprehensive review; used for historical context and traditional use verification.
- Blumert, Michael, and Jialiu Liu. Jiaogulan: China’s Immortality Herb. Badger, 2003.English-language popular reference on Jiaogulan. Used for the Jiuwan village narrative and traditional preparation methods.
- Ministry of Public Health of China. “Notice on Further Standardizing the Management of Functional Foods.” China Food and Drug Administration, 5 Mar. 2002, www.nhc.gov.cn/.Official classification of Gynostemma as a functional food. Used in Section I.
- Ministry of Science and Technology of China. “Spark Program Development Plan.” 1986. State Council of China, www.most.gov.cn/.First designation of Gynostemma as a “precious Chinese medicine.” Used in Section I.
Image credit: Young jiaogulan plant By Dr.T. Voekler – Own work, CC BY-SA 3.0, https://commons.wikimedia.org/w/index.php?curid=20372634
Disclaimer:
This article is for educational purposes and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician before making health decisions based on the TyG Index or other biomarkers.
© 2018 – 2026 Asclepiades Medicine, LLC. All Rights Reserved
DrJesseSantiano.com does not provide medical advice, diagnosis, or treatment
As an Amazon Associate, I earn from qualifying purchases
Discover more from Don't Get Sick!
Subscribe to get the latest posts sent to your email.